Ones To Watch News
Refine Search
Biotechnology
German biotech Abalos Therapeutics has announced the appointment of Thomas Bogenrieder as chief medical officer (CMO). 18 October 2022
Biotechnology
After several setbacks in its product development and partnering deals in the last few years, US oncology focussed biotech AVEO Oncology has agreed to be acquired by South Korea’s LG Chem. 18 October 2022
Pharmaceutical
US neurological diseases specialist Acorda Therapeutics saw its shares go stratospheric yesterday, after it revealed it has been awarded $16.5 million by an arbitral panel following a dispute with Ireland-incorporated drugmaker Alkermes over licensing royalties for the multiple sclerosis drug Ampyra (dalfampridine). 18 October 2022
Biotechnology
Biotech major Gilead Sciences has entered an exclusive option and collaboration agreement with fellow USA-based Macrogenics to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and two additional bispecific research programs. 17 October 2022
Pharmaceutical
US clinical-stage firm Reata Pharmaceuticals edged up 2.6% to $25.05 yesterday, when it puzzled investors with the news that the US Food and Drug Administration (FDA) has decided not to hold an advisory committee (AdCom) meeting in connection with its review of the company’s New Drug Application (NDA) for omaveloxolone for the treatment of patients with Friedreich’s ataxia. 14 October 2022
Biotechnology
Troubled Boston, USA-based rare disease specialist Imara saw its shares rise 4.4% yesterday and a further 17% to $3.01 pre-market today, after a planned merger with fellow USA-based Enliven Therapeutics was revealed. 14 October 2022
Biotechnology
Sino-American biotech BeiGene shot up on Wednesday, after the company's chronic lymphocytic leukemia (CLL) treatment was shown to beat out a blockbuster drug from Johnson & Johnson. 13 October 2022
Pharmaceutical
French therapeutic peptides for rare endocrine and metabolic diseases company Amolyt Pharma today announced positive Phase IIa safety and efficacy data from the second cohort of its ongoing clinical trial evaluating its lead candidate, AZP-3601, in patients with hypoparathyroidism. 12 October 2022
Biotechnology
Neumora Therapeutics, a US clinical-stage biotech focussed on brain diseases through the integration of data science and neuroscience that came out of stealth in July last year with $500 million financing, has added to its cash pile announcing today the close of a $112 million Series B financing. 11 October 2022
Biotechnology
Singapore-based TauRx Pharmaceuticals, a company that claims to be the global leader in tau-based research in Alzheimer’s disease, recently reported positive progress for the firm's lead investigative oral drug hydromethylthionine mesylate (HMTM). The drug was found to be effective in improving cognition in patients with early Alzheimer’s disease (AD). 11 October 2022
Pharmaceutical
UK clinical stage drug development company Evgen Pharma saw its shares rocket more than 66% to 4.63 pence this morning, after it revealed the signing of global license for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. 10 October 2022
Biotechnology
Following a board decision to terminate the mandate of Alexis Vandier, France-based biotech OSE Immunotherapeutics (Euronext: OSE) has appointed Dr Nicholas Poirier as its chief executive, with immediate effect. 8 October 2022
Biotechnology
Even before the diabetes candidate gets regulatory approval, US biotech Provention Bio revealed it has entered into a co-promotion agreement with French pharma major Sanofi for the launch of Provention's lead investigational drug candidate teplizumab. 7 October 2022
Biotechnology
Germany’s BioNTech, which leapt into the limelight from near obscurity through the development of the most successful COVID-19 vaccine (Comirnaty) with US pharma giant Pfizer (NYSE: PFE), has since been expanding its strong mRNA platform into other therapy areas and regions, demonstrating that it is not just a one trick pony. 7 October 2022
Pharmaceutical
LifeMine Therapeutics, a US start-up searching the fungal biosphere for genetically-encoded small molecules (GEMs), today announced the appointments of Martin Stahl, as chief scientific officer and Louis Plamondon, as executive vice president and head of CMC. 6 October 2022
Biotechnology
Privately-held US biotech company ImaginAb has had what it has describes as ‘a transformational year’ in an update on its achievements over the year. 4 October 2022
Biotechnology
Neurodegenerative disease specialist company Clene closed 28% lower after Monday’s trading. 4 October 2022
Pharmaceutical
Melatonin, a natural hormone that is produced by the pineal gland and used by many long-haul airline travellers to mitigate their jet-lag symptoms, has gained its first approval in the UK, but as a treatment for sleep onset insomnia in children and adolescents aged six-17 years with attention-deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been inadequate. 4 October 2022
Generics
Indian generics major Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to market mirabegron extended-release tablets USP 25mg and 50mg. 3 October 2022
Biotechnology
Aiming to add to its vitiligo arsenal, US biopharma firm Incyte today announced that it has entered into an agreement to acquire Villaris Therapeutics, in a deal that could cost it as much as $1.4 billion. 3 October 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze